In May 2017, China Stroke Conference and the Seventh National Forum on Cardiovascular and Cerebrovascular Diseases were held in full swing at the Beijing National Conference Center. On the afternoon of May 20, “China’s Guidelines for Rational Use of Chinese Patent Medicine for Ischemic Stroke”, which was established by many famous TCM and western medicine experts, was grandly issued and launched its national tour. Guo Rongjuan, Deputy Director of Dongfang Hospital of Beijing University of Chinese Medicine presided over the meeting. Chao Baohua, Chief of Stroke Prevention Office with National Commission of Health and Family Planning, Zhang Yunling, Director of Dongfang Hospital of Beijing University of Chinese Medicine, Huang Xiaobo, Professor with Xuanwu Hospital of Capital Medical University, Hu Fengyun, Professor with Shanxi People’s Hospital, Zhang Hongyu, Deputy General Manager of Angong Niuhuang Pill Sales Company with Beijing Tongrentang Investment Group Co., Ltd, and journalists from over 20 medias attended the meeting.
First, Chief Chao Baohua released and introduced “China’s Guidelines for Rational Use of Chinese Patent Medicine for Ischemic Stroke” (hereinafter referred to as “Guidelines”): the clinical use of Chinese patent medicines in the treatment of ischemic stroke has become more and more extensive, as many doctors of western medicine also adopt them in clinical treatment and have achieved good results. In order to promote clinical rational and safe use of medicine, prevent the occurrence of adverse drug reactions, and improve the clinical efficacy, a compiling group of TCM and western medicine experts was organized to compile the Guidelines after repeated demonstration and discussions, in an effort to promote its application nationwide and standardize clinical physicians’ rational use of Chinese patent medicine.
Then, Hospital Director Zhang Yunling, as the Head of the compiling group, made an explanation on the Guidelines: the Guidelines was compiled on the basis of previous relevant guidelines, with the principles of absorbing the latest research evidence, combining Chinese national conditions, highlighting TCM characteristics and improving clinical operability. It covers the whole course of prevention and treatment of ischemic stroke, such as aura, acute stage, recovery stage, sequela period and main complications. It fully reflects the TCM treatment strategy of equal attention to prevention and treatment and whole course management. The content of the compilation focuses on the clinical thinking process of Chinese medicine. Through the demonstration and recommendation of Chinese patent medicines, it inspires the doctors to draw inferences about other cases and flexibly grasp and apply them, especially for Western doctors. The main purpose is to standardize the rational use of Chinese patent medicine in clinical practice under the guidance of the theory of TCM syndrome differentiation and treatment. The Guidelines needs to be continuously revised and improved in clinical practice
After that, Deputy General Manager Zhang Hongyu, on behalf of Beijing Tongrentang Investment Group, said that it was enterprises’ social responsibility to actively take part in stroke prevention and treatment and announced the launch of the national tour of the Guidelines. Chief Chao Baohua and Hospital Director Zhang Yunling led the participants to hold the launch ceremony.
The Guidelines will be officially published by People’s Health Publishing House before October 2017. With its release and national tour, a new stroke prevention and treatment mode of Chinese characteristics with integrated traditional Chinese and western medicine will be constructed, in an effort to make a major breakthrough in stroke prevention and treatment in China.
(Encephalopathy team with Dongfang Hospital of Beijing University of
Chinese Medicine, Zhang Qihui, Lu Tiange)
